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During July 2014 the International AIDS Conference, AIDS 2014 was held in 14 
Melbourne, Australia. Approximately 13,600 delegates took part, and this brief report 15 
from an Australian pharmacist who attended, outlines some of the drug-related 16 
developments discussed during the six-day meeting. There is also an AIDS 2014 17 
YouTube channel through which many sessions from the conference can be 18 
accessed without charge.  19 
 20 
Background on HIV in Australia 21 
 22 
At the end of 2013 there were approximately 27,000 people living with Human 23 
Immunodefiency Virus (HIV) infection in Australia (1). There were 1,236 new cases 24 
reported in 2013 and 70% of newly diagnosed cases were sexually transmitted 25 
between men who have sex with men (MSM). Nearly half of the 313 newly 26 
diagnosed cases acquired through heterosexual transmission were in people from 27 
high-prevalence countries or their partners. Thirty percent were late presentations, 28 
defined as a CD4 cell count of less than 350 cells/µL at the time of diagnosis. After a 29 
marked downward trend in new diagnoses during the 1990’s, there has been a 30 
steady increase from 1999 when 724 new cases in Australia were diagnosed.  31 
An estimated 49-73% of those living with HIV (whether diagnosed or not) and 57-32 
84% of those who have been diagnosed were on effective antiretroviral therapy 33 
(ART) at the end of 2013. These numbers demonstrate that while Australia remains 34 
a low HIV prevalence country, some barriers to diagnosis and treatment remain.  35 
 36 
At a special ‘Australia session’ during the conference the nation’s Chief Medical 37 
Officer discussed the Seventh National HIV Strategy 2014-2017 (2). One of the 38 
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goals of the strategy is to “work towards achieving the virtual elimination of HIV 39 
transmission in Australia by 2020” and several presentations explored ways of 40 
achieving this ambitious goal. One presentation was provided by Cameron Cox, a 41 
sex worker who described his outreach role at the Sex Workers Outreach Project 42 
(SWOP) in New South Wales (3). He discussed the use of social media, including 43 
through popular “hook-up” sites, as an effective means of reaching male sex 44 
workers, a population who describe that they do not always feel they want to be the 45 
recipients of outreach services.  46 
 47 
In the lead up to the conference, changes to prescribing and dispensing of 48 
antiretrovirals (ARVs) were announced by the Australian Government Department of 49 
Health (4). These changes will allow for the dispensing of ARVs from community 50 
pharmacies as well as hospitals from 1 July 2015. From the same date, prescribers 51 
will no longer have to demonstrate an affiliation with a hospital to prescribe ARVs, 52 
though all other requirements for Section 100 prescribing under the auspices of the 53 
Pharmaceutical Benefits Scheme will remain the same. Restrictions on home-testing 54 
kits for HIV have also been lifted so that companies producing these can now apply 55 
to the Australian Therapeutic Goods Administration for registration to allow sale 56 
directly to the public.  57 
 58 
New developments with ARVs  59 
 60 
ARVs are well-established as an effective treatment for HIV and the wide availability 61 
of fixed-dose combinations (e.g. Atripla ® - efavirenz 600 mg/ emtricitabine 200 mg/ 62 
tenofovir disoproxil fumarate 300 mg), rendering the dosing regimens in current use 63 
4 
 
considerably less complex than was the case during earlier stages of the pandemic. 64 
Most of the discussion of ART at the conference related to increasing testing and 65 
subsequent access to these drugs by effecting society-level cultural and legislative 66 
change to reduce stigma around HIV, especially in high-prevalence countries. 67 
Another major theme of the conference related to the ways that ARVs can be used 68 
to prevent infection with HIV – a summary is provided in table 1.  69 
 70 
In recent times, another strategy referred to as oral Pre-Exposure Prophylaxis 71 
(PrEP) has been evaluated to determine if ARVs can reduce transmission of HIV if 72 
people who are HIV-negative, but who are at a high risk of infection, take them 73 
prophylactically. There is a growing number of randomised controlled trials (RCTs) 74 
that have assessed the efficacy of PrEP as part of a HIV prevention strategy. Results 75 
of trials where PrEP has been evaluated in heterosexual participants at high risk of 76 
HIV infection have been mixed, and outcomes appear to be closely linked with 77 
adherence to therapy. The phase 3, multi-country, placebo-controlled iPrEx trial (N = 78 
2,499) found a 44% reduction in HIV incidence with tenofovir disoproxil fumarate 79 
(TDF)/ emtricitabine (FTC) PrEP versus placebo (p = 0.005) amongst MSM and 80 
transgender women who have sex with men, with efficacy again linked with 81 
adherence (8). Both active and placebo arms of the iPrEx trial were offered a 82 
package of HIV reduction strategies (condoms, HIV testing and so on). The available 83 
trial data for PrEP use with TDF/FTC and TDF alone in heterosexual, MSM and 84 
transgender populations are summarised in recently published clinical practice 85 
guidelines from the USA (9). Currently only combination TDF/FTC (Truvada ®) is 86 




At the AIDS 2014 conference, data from the iPrEx open label extension (OLE) trial 89 
were presented and simultaneously published in the Lancet Infectious Diseases (10, 90 
11). Previous iPrEx participants were invited to be involved, resulting in the 91 
recruitment of 1,603 participants from 11 study sites. The study was of 72 weeks 92 
duration and 76% of participants elected to take daily TDF/FTC PrEP.  This study 93 
aimed to assess the efficacy of PrEP when provided to participants who knew that 94 
the intervention was TDF/FTC and not a random chance of active or placebo, as was 95 
the case in the original iPrEx trial. As with previous PrEP RCTs, efficacy was 96 
correlated with adherence to treatment. Notably, dried blood spot analysis of TDF 97 
levels showed that no participants taking four or more tablets per week became 98 
infected with HIV during the study period. In a presentation of a qualitative sub-study 99 
of the iPrEx OLE by Kimberly Koester, it was reported that use of PrEP did not lead 100 
to ‘risk compensation’ such as the lower use of other preventative strategies such as 101 
condoms (12). Instead, these researchers found that the use of PrEP was 102 
associated with less anxiety about being infected with HIV during sex.  103 
 104 
Preliminary adherence results from pilot sites of the IPERGAY study being 105 
conducted in France and Canada were also presented, assessing a strategy of ‘on 106 
demand’ rather than regular PrEP dosing (13). Participants are randomised to 107 
receive TDF/FTC PrEP or placebo and are asked to take two tablets, two to 24 hours 108 
prior to sex and another tablet once daily for two days following. Participants are also 109 
offered a treatment package to reduce HIV infection risk as part of their involvement. 110 
Early data indicates a high adherence rate to this approach, though not always taken 111 
exactly as directed. Adherence was measured through computer-assisted self-112 
interviews, tablet counts, plasma and scalp hair (when this was available) 113 
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concentrations of TDF and FTC. This trial is ongoing with planned completion in late 114 
2016 (14).  115 
 116 
The World Health Organization has this year released a revised strong 117 
recommendation that PrEP should be offered to MSM as part of a range of options to 118 
reduce risk of being infected with HIV (15). Other options include the use of condoms 119 
and lubricants, routine HIV testing, risk-reduction counselling and adherence 120 
counselling if PrEP is offered. In Australia, the Victorian PrEP HIV Demonstration 121 
Project (VicPrEP study) is being led by Associate Professor Edwina Wright of 122 
Monash University to assess the efficacy and acceptability of PrEP in Australia, 123 
when combined with other risk reduction strategies (16). Researchers plan to enroll 124 
100 participants at risk of HIV infection who elect to use PrEP, and to compare 125 
outcomes to another 100 participants who do not wish to receive PrEP, following 126 
both groups for 12 months. It is noteworthy that no ARVs are currently licensed for 127 
use in a PrEP context in Australia (outside of demonstration projects). The VicPrEP 128 
study, along with others planned in Queensland and New South Wales (17), should 129 
yield important data to support future policy decisions around PrEP, as it is still a 130 
very new approach to HIV prevention.   131 
 132 
HIV doesn’t exist in isolation: viral hepatitis and tuberculosis advances  133 
 134 
At the conference, the results from trials focusing on the drug treatment of viral 135 
hepatitis and tuberculosis (TB) treatment were also presented. Viral hepatitis and 136 
HIV share common risk factors for transmission, especially for those people who 137 
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inject drugs (10). TB is the leading cause of HIV-associated deaths globally, and 138 
naturally was also an important focus for the conference (15). 139 
 140 
Trial data assessing the efficacy of newer, direct-acting antiviral regimens for 141 
patients co-infected with viral hepatitis C (HCV) and HIV showed similar treatment 142 
outcomes to those seen with HCV mono-infected patients. These findings support 143 
the 2014 European Association for the Study of the Liver (EASL) recommendation 144 
that for chronic HCV “the same treatment regimens can be used in HIV co-infected 145 
patients as in patients without HIV infection, as the virologic results of therapy are 146 
identical” (18, p. 5).  147 
 148 
Phase 2B trial results were presented for PaMZ, an anti-TB regimen containing a 149 
new nitroimidazole currently referred to as PA-824 (used at a dose of 100 mg or 200 150 
mg daily), plus Moxifloxacin (M - 400 mg daily) and pyrazinamide (Z - 1,500 mg 151 
daily) (19, 20). Patients with drug-sensitive and multi-drug resistant (MDR) TB, 152 
defined as resistance to rifampicin and isoniazid, were enrolled from study sites in 153 
South Africa and Tanzania. In all, 207 patients were enrolled (20% with HIV co-154 
infection) and 173 were included in the final analysis: 164 with drug-sensitive TB and 155 
9 with MDR-TB. Patients with drug-sensitive TB were randomly assigned to receive 156 
either PaMZ or a standard, weight-based, anti-TB regimen containing rifampicin, 157 
isoniazid, pyrazinamide and ethambutol (RHZE). There was no comparator for the 158 
MDR-TB patient group and these patients all received the higher dose of PA-824. 159 
PaMZ yielded good results, with a primary endpoint of reduction in colony forming 160 
units of Mycobacterium tuberculosis from sputum samples taken over eight weeks 161 
(at day 0, 3, 7 and then weekly thereafter). The log reduction per day was greater 162 
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than the RHZE regimen (N=54) for each of the PaMZ groups and this difference was 163 
statistically significant (p< 0.05) for the Pa (200mg) MZ drug-sensitive TB group (N = 164 
56). These results were unchanged when adjusted for HIV status. The follow on 165 
Phase 3 study is planned to commence this year, aiming to assess the efficacy of 166 
PaMZ over a full treatment course. The researchers plan to enroll 1,500 patients; 167 
drug-sensitive TB treatment duration will be for four or six months and MDR-TB 168 
treatment will be for six months. With current regimens for MDR-TB treatment taking 169 
18 - 24 months to complete, the results of this trial will be watched for closely. Other 170 
clinical trials assessing the efficacy of shorter MDR-TB treatment regimens are also 171 
underway.  172 
 173 
Future directions in HIV  174 
 175 
A lot of discussion during the AIDS 2014 conference focused on advances in basic 176 
science. Rather than the term cure, most of the sessions referred to achieving 177 
sustained HIV remission. Presentations focused on areas such as the anatomical 178 
distribution of enduring HIV viral reservoirs, HIV viral latency and studying the natural 179 
immune response to HIV infection, particularly through the production of broadly 180 
neutralising antibodies. The cases of the ‘Mississippi baby’ (born with HIV to a  181 
HIV-positive mother, with undetectable viral load after early ART - 18 months of 182 
treatment commencing 30 hours after delivery - but recently relapsed after 27 183 
months testing HIV-negative without ART), the two ‘Boston patients’ (initially thought 184 
to cleared of HIV infection following bone marrow transplants but later relapsing), 185 
Timothy Ray Brown (the ‘Berlin patient’ - who no longer requires ART following bone 186 
marrow transplantation in 2007 and 2008 with donor cells deficient in a co-receptor 187 
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called CCR5) and the VISCONTI cohort (14 French patients given ART soon after 188 
becoming infected with HIV and achieving a sustained “functional cure”, with no HIV 189 
viral rebound despite ARVs no longer being taken), were frequently mentioned. 190 
These seminal cases present opportunities to advance our understanding of 191 
potential ways to access the small amount of HIV retrovirus that remains integrated 192 
with host cell DNA, even in patients that are well-controlled on ART.  193 
 194 
Focus on the here and now 195 
 196 
There are many tools available for the prevention and treatment of HIV available 197 
now. This is especially the case in Australia, where many of the legislative, logistics 198 
and cultural barriers to effective HIV control that exist elsewhere are absent, or at 199 
least far less significant than in other parts of the world. Through working with 200 
sectors outside of health and using a pragmatic approach to provide information to 201 
those most at risk of acquiring HIV without prejudice, the incidence of HIV in 202 
Australia can be reduced with the array of scientific strategies that are currently 203 
available. 204 
 205 
  206 
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Description  Suggested further reading (accessible by typing 




Yes Early treatment of HIV-positive patients with 
ART was shown to reduce the risk of sexually 
transmitting HIV to a seronegative partner by 
96% amongst an almost exclusively 
heterosexual cohort, in early results of the 
HPTN-052 trial (5). The two arms of this study 
compared; 1) the HIV-positive partner starting 
ART with a CD4 count between 350-550 
cells/mm3, and 2) the HIV-positive partner 
starting treatment when the CD4 count fell 
 
Australasian Society for HIV Medicine. 2014 DHHS 
guidelines for the use of antiretroviral agents in HIV-
1 infected adults and adolescents with Australian 




below 250 cells/mm3 or if AIDS-related illness 
developed. The ongoing PARTNER study has 
also shown the potential of TasP, this time 
looking and serodiscordant heterosexual and 
homosexual couples where the HIV-positive 
partner is already virally suppressed on ART 
(6). Promising preliminary results for this study 
were presented at the Conference on 
Retroviruses and Other Infections (CROI) 2014 
(7). There remains uncertainty regarding when 
exactly to start ART for HIV-positive patients 
and recent Australian-adapted guidance on 
this is provided in the further reading column. 
TasP reduces but does not eliminate the risk of 
HIV transmission and should be combined with 
other HIV prevention strategies such as correct 
16 
 
and consistent condom use and safe injecting 
practices. The Australian, “Opposites Attract” 
study aims to test the efficacy of TasP amongst 
serodiscordant homosexual couples and is 
currently recruiting in Sydney, Melbourne, 





Yes People that have potentially been exposed to 
HIV (through sexual contact, needle-stick injury 
etc.) can be offered a 28-day course of ARVs. 
The decision to offer PEP and regimen 
prescribed is based on the type of exposure 
and the risk of the source being HIV-positive, if 
the HIV status of the source is unknown. PEP 
must be commenced within 72 hours of 
exposure.  
Australasian Society for HIV Medicine. Post-
exposure prophylaxis after non-occupational and 
occupational exposure to HIV: national guidelines. 
Darlinghurt, NSW: 2013. 
 







HIV transmission to a baby from a HIV-positive 
mother. Not all ARVs are safe in pregnancy 
and dosing regimens can vary depending on 
the situation, specialist advice should be 
sought. Mother-to-child HIV transmission is 
very rare in Australia, with an average of one 
case per year over the past decade (1). The 
further reading references material aimed at 
consumers with links to other resources. 
Channel. HIV and women - having children [web 





No  Refer to main text for more in-depth discussion. 
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